Bifidobacterium breve Bif195改善阿司匹林诱导的胃粘膜损伤:一个随机,双盲,安慰剂控制的交叉试验
Nina Løn1, Sara Engel2, Anders Damholt2
1Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Alimentary pharmacology & therapeutics
|November 30, 2023
概括
Bifidobacterium breve Bif195 (Bif195) 补充剂在健康志愿者中显著降低了阿司匹林诱导的胃损伤. 这种益生菌可能是预防长期阿司匹林治疗期间胃肠道副作用的安全方法.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多剂量阿司匹林治疗,常用于预防心血管疾病,经常导致胃和十二指肠.
- 细菌菌株Bifidobacterium breve Bif195 (Bif195) 已经显示出减少阿司匹林诱导的小肠损伤的潜力.
- Bif195的保护作用机制,特别是关于循环氧酶-2 (COX-2) 抑制的机制,需要进一步研究.
研究的目的:
- 评估Bifidobacterium breve Bif195 (Bif195) 在预防阿司匹林诱导的胃和十二指肠粘膜损伤方面的疗效.
- 评估Bif195与阿司匹林联合使用时的安全性.
- 确定Bif195对肠道粘膜完整性的内镜测量的影响.
主要方法:
- 一项随机,双盲,安慰剂控制的交叉研究,涉及25名健康志愿者.
- 参与者接受了两次为期4周的干预期,接受阿司匹林 (每天300毫克) 加Bif195 (每天≥10^11个殖民地形成单位) 或阿司匹林加安慰剂.
- 为了评估粘膜损伤,使用Lanza评分进行了胃管腺镜检查,干预之间有6周的洗期.
主要成果:
- 所有参与者完成了试验,与基线相比,在安慰剂治疗期间观察到的Lanza得分 (表明粘膜损伤) 显著增加.
- 与安慰剂相比,Bif195补充剂导致胃Lanza得分显著降低 (几率比7.2,p=0.009).
- 在十二指肠中没有观察到Lanza得分的显著变化,也没有报告与Bif195相关的不良事件.
结论:
- Bifidobacterium breve Bif195 (Bif195) 有效地减少了阿司匹林引起的胃粘膜损伤.
- Bif195表现出良好的安全性,没有报告任何不良事件.
- 对于接受长期阿司匹林治疗以减轻胃肠道副作用的人来说,Bif195可以作为有益和安全的补充剂.
相关概念视频
01:26Peptic Ulcer Disease IV: Management
95
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
95
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
449
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
449
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
499
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
499
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
435
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
435
01:17Gastritis-II: Pathophysiology
344
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
344
01:29Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145